IRIX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-18

• Other expense, net, was $167 thousand and $33 thousand, respectively, for the three months ended July 4, 2026 and June 28, 2025, primarily consisting of interest and amortization of loan expenses.

• The following comparisons are between the six months ended July 4, 2026 and June 28, 2025 (in thousands):

• Our total revenues decreased by $1.1 million, or 4.3%, from $25.5 million to $24.4 million. Revenue in our retina product group decreased, partially offset by an increase in our glaucoma and other revenue product groups.

• While we believe that the market for our products remains strong, the overall capital expenditure landscape within hospitals, surgical centers and physician offices may continue to be negatively impacted by persistent macroeconomic concerns, including those from ongoing geopolitical uncertainties, i…

• Gross profit decreased by $0.7 million, or 7.2% from $9.7 million to $9.0 million. Gross margin decreased by 1.1% from 38.2% to 37.1%. The decrease in gross margin was primarily due to higher manufacturing costs and increased product costs related to recent tariff developments as the Company continu…

相对上期删除的文字 · 来源:10-Q · 2026-05-19

• Other expense, net, was $0.1 million for the three months ended April 4, 2026, primarily consisting of interest and amortization of loan expenses. Other expense, net, was $1.5 million for the three months ended March 29, 2025, driven primarily by the costs associated with the Lind Note payable settl…

• We have incurred net losses over the last several years, and as of April 4, 2026, have an accumulated deficit of approximately $92.9 million.

• We believe our existing cash and cash equivalents will be sufficient to meet our anticipated cash needs over the next 12 months. Our future capital requirements will depend on many factors, including our growth rates, the timing and extent of our spending to support research and development activiti…